Prof. Dr. Roger Schibli
Head of the Center for Radiopharmaceutical Sciences ETH-PSI-USZ
5232 Villigen PSI
Prof. Roger Schibli is an Associate Professor in the Department of Chemistry and Applied Biosciences (ETH Zurich) since 2010, and Head of the Center for Radiopharmaceutical Science (CRS), a joint endeavor between the ETH Zurich, the Paul Scherrer Institute and the University Hospital Zurich. Prof. Schibli studied Chemistry at the University of Basel, Switzerland and performed his doctoral thesis under the supervision of Prof. Thomas Kaden. After his graduation, he spent two years at the University of Missouri-Columbia, MO as a post-doctoral fellow. He was appointed Assistant Professor (tenure track) for Therapeutics Technologies at the Institute of Pharmaceutical Sciences (ETH Zurich) in 2004 and was tenured in 2009.
Prof. Schibli's research interestscover targeted tumor diagnosis and therapy using radiolabeled compounds. Apart from the chemical modification and radioactive labeling of molecules, his group emphasizes on the biological and pharmacological characterization and optimization of the radioactive compounds including non-invasive PET and SPET imaging. New, medically relevant radionuclides for his pre-clinical and clinical studies are produced at the cyclotron and neutron facilities of the ETH and the Paul Scherrer Institute.